# US 7,608,698 B2 · Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,698 B2
- Document ID: US7608698B2
- Status: Granted
- Kind: B2
- Application number: 10/154,386
- Filed: 2002-05-23
- Published: 2003-02-06
- Granted: 2009-10-27
- Earliest claimed: 2001-05-23
- Assignees: Angiogene Inc.
- Inventors: Louis-Georges Guy; Anouk Fortin
- Web page: https://patentgrep.com/patent/US7608698B2

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides HIF-3α nucleic acid and sequences. Also provided are methods for using HIF-3α nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3α, modulate HIF-3α cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals.

## Claims

### Claim 1

An isolated or purified nucleic acid comprising a nucleotide sequence selected from the group consisting of:
the nucleotide sequence of SEQ ID NO: 1;
the nucleotide sequence that is fully complementary to the nucleotide sequence of SEQ ID NO: 1; and
nucleotide sequences having at least 95% identity to the full length of the nucleotide sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein it comprises a nucleotide sequence having at least 95% nucleotide sequence identity to the full length of a nucleic acid encoding the amino acid sequence of SEQ ID NO: 2.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein it encodes a polypeptide having the biological activity of a human Hypoxia Inducible Factor-3 (HIF-3) polypeptide.

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein said nucleic acid consists of a cDNA.

### Claim 5 (depends on 1)

A cloning or expression vector comprising the nucleic acid of claim 1.

### Claim 6 (depends on 5)

The vector of claim 5, wherein said vector is capable of directing expression of a peptide encoded by said nucleic acid in a vector-containing cell.

### Claim 7 (depends on 5)

The vector of claim 5, wherein said vector is selected from the group consisting of plasmids, cosmids, artificial chromosomes, adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, alphaviruses, and lentiviruses.

### Claim 8 (depends on 1)

A transduced cell that contains the nucleic acid of claim 1.

### Claim 9 (depends on 8)

The cell of claim 8, wherein said cell consists of a cell selected from the group consisting of HEK293 cells, Hep3B cells, mammalian skeletal muscular cells, cardiac cells, bone marrow cells, fibroblasts, smooth muscle cells, endothelial cells, endothelial progenitor cells and embryonic stem cells.